Core D: Neuropathology Core

核心D-抽象 加州大学旧金山分校ADRC神经病理学、生物显微镜和遗传学核心(NP核心，核心D)提供至关重要的 对加州大学旧金山分校ADRC和加州大学旧金山分校神经退行性疾病研究社区的研究支持 更远一点。神经退行性疾病的病理学和遗传学已经变得越来越令人兴奋和复杂 近年来，通过这个亚洲发展研究中心完成的工作取得了重大进展。在这次更新中 在申请之后，国家核核心将继续由威廉·西利博士领导。Lea Grinberg博士将发现一种新的 Biosecimens亚核，Dan Geschind博士和Giovanni Coppola博士将继续领导遗传学 加州大学洛杉矶分校的次核。NP Core的目标是：(1)获取和储存用于神经病理的人体生物材料， 生化和遗传特征；(2)分析标本并记录结果，包括NP 使用当前诊断共识标准提供的诊断，以及(3)进入NP、生物测定和遗传学 将结果存入以研究为导向的数据库并分发标本。这些核心职能将支持目标 项目1(Eoad变种)、2(PPA异质性)和3(IPSC模型)通过提供最终的 神经病理诊断，组织和进行生化分析，并提供基因分型和 基因表达分析。此外，NP核心将有助于进一步发展一个独特的专门银行 处理的材料(脑、脊髓、脑脊液、血浆、尿液、RNA/DNA)用于正在进行的和未来的分子， 翻译、临床病理和生物标记物发现研究。

CORE D - ABSTRACT The UCSF ADRC Neuropathology, Biospecimens, and Genetics core (NP core, Core D) provides vital research support to the UCSF ADRC and to the neurodegenerative disease research community at UCSF and beyond. Neurodegenerative disease pathology and genetics have become increasingly exciting and complex in recent years, with major advances arising from work accomplished through this ADRC. In this renewal application, the NP Core will continue to be led by Dr. William Seeley. Dr. Lea Grinberg will found a new Biospecimens sub-core, and Drs. Dan Geschwind and Giovanni Coppola will continue to lead the Genetics sub-core at UCLA. The NP Core aims to: (1) Obtain and bank human biomaterial for neuropathological, biochemical, and genetic charaterization; (2) Analyze specimens and document results, including NP diagnoses rendered using current diagnostic consensus criteria, and (3) Enter NP, bioassay, and genetics results into research-oriented databases and distribute specimens. These core functions will support the aims of Projects 1 (EOAD variants), 2 (PPA heterogeneity), and 3 (iPSC models) by providing final neuropathological diagnoses, organizing and conducting biochemical analyses, and providing genotyping and gene expression analysis. Moreover, the NP Core will help to further develop a unique bank of specially handled materials (brain, spinal cord, CSF, plasma, urine, RNA/DNA) for ongoing and future molecular, translational, clinicopathological, and biomarker discovery research.